Find, compare & contact
Sugemalimab
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sugemalimab API 2256084-03-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sugemalimab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sugemalimab
- Synonyms:
- CS 1001 , Sugemalimab
- Cas Number:
- 2256084-03-2
- DrugBank number:
- DB16641
- Unique Ingredient Identifier:
- 90IQR2I6TR
General Description:
Sugemalimab, identified by CAS number 2256084-03-2, is a notable compound with significant therapeutic applications. Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma. It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL and orphan drug designation to treat T-cell lymphoma. During studies, sugemalimab was well tolerated and has shown antitumor activity in multiple tumor types. Sugemalimab is under investigation in clinical trial NCT03802591 (A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-esophageal Junction Adenocarcinoma).
Mechanism of Action:
Sugemalimab functions by: Sugemalimab, a monoclonal antibody, targets the programmed death-ligand 1 (PD-L1). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Sugemalimab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.
Sugemalimab is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.